Selected article for: "acid vaccine and live inactivated"
Author: Opriessnig, Tanja; Mattei, Ashley A.; Karuppannan, Anbu K.; Halbur, Patrick G.
Title: Future perspectives on swine viral vaccines: where are we headed?
  • Cord-id: 9nwj7mz8
  • Document date: 2021_1_4
    • ID: 9nwj7mz8
    Snippet: Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essen
    Document: Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and additional safety: 1
    • action mechanism and adenovirus vector: 1
    • active infection and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection risk and acute respiratory sars syndrome: 1, 2, 3, 4
    • acute respiratory sars syndrome and additional people: 1
    • acute respiratory sars syndrome and additional safety: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory sars syndrome and adenovirus platform: 1, 2
    • acute respiratory sars syndrome and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23